Skip to main content
Sona Nanotech Inc. logo

Sona Nanotech Inc. — Investor Relations & Filings

Ticker · SONA ISIN · CA83541C1059 CSE Professional, scientific and technical activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2020-04-13 Capital/Financing Update
Country CA Canada
Listing CSE SONA

About Sona Nanotech Inc.

https://www.sonanano.com/

Sona Nanotech Inc. is a life sciences company specializing in the development and commercialization of proprietary, uniquely biocompatible gold nanorod (GNR) technology. The primary therapeutic focus is Targeted Hyperthermia Therapy (THT), a photothermal cancer treatment utilizing GNRs to deliver precision heat directly to solid tumors. THT is designed to reduce tumor burden and stimulate immunogenic cell death while minimizing harm to healthy tissue. Sona is advancing THT through clinical trials for solid cancers, including melanoma. Furthermore, the company manufactures and supplies its patented, CTAB-free gold nanoparticles (nanorods and nanospheres) for integration into advanced materials science and medical diagnostic applications, such as lateral flow assays.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release providing a progress update on the development and manufacturing arrangements of Sona Nanotech's Covid-19 antigen test. It includes information about prototype testing, manufacturing MOUs, pre-orders, and trading approval on OTCQB. There are no financial statements, regulatory certifications, voting results, or detailed financial data. The content is an operational update rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate update announcement about product development progress and business arrangements, which aligns best with the Capital/Financing Update category as it discusses manufacturing agreements and pre-orders, which relate to capital and financing activities.
2020-04-13 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification form titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS' by the CEO of Sona Nanotech Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended January 31, 2020. The text explicitly states it is a certification of interim filings, not the filings themselves. The document is short (3041 characters) and primarily an officer certification letter, with no actual financial data or detailed interim report content included. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2020-04-03 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification form titled 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS' by the CFO of Sona Nanotech Inc. It certifies the review and fair presentation of interim financial statements and interim MD&A for the period ended January 31, 2020. The text explicitly states it is a certification of interim filings, not the filings themselves. The document is short (3047 characters) and primarily an officer certification letter, which aligns with the CERTIFICATION RULE. Therefore, it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or any other report type.
2020-04-03 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-04-03 English
Interim MD&A - English.pdf
Regulatory Filings
2020-04-03 English
Form of proxy - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a $25 million bought deal private placement by NanoXplore Inc. It details the financing transaction, including the number of shares issued, the price per share, the use of proceeds, and participation by insiders and strategic partners. There is no presentation of financial statements or detailed financial performance data. The document focuses on capital raising and corporate updates related to financing activities. It is not an annual or interim report, audit report, earnings release, or any other type of financial report. The content clearly fits the definition of a Capital/Financing Update, which covers company fundraising and financing activities.
2020-04-03 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.